is unknown. b. anti-hiv protease inhibitors several of the anti-hiv protease inhibitors have been studied with coadministration of oral combination hormonal contraceptives; significant changes (increase and decrease) in the plasma levels of the estrogen and progestin have been noted in some cases. the efficacy and safety of these oral contraceptive products may be affected with coadministration of anti-hiv protease inhibitors. healthcare providers should refer to the label of the individual anti-hiv protease inhibitors for further drug-drug interaction information. concomitant use with hcv combination therapy – liver enzyme elevation do not co-administer velivet (desogestrel and ethinyl estradiol tablets) with hcv drug combinations containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir, due to potential for alt elevations (see warnings, risk of liver enzyme elevations with concomitant hepatitis c treatment ). c. herbal products herbal products containing st. john’s wort (hypericum perforatum) may induce hepatic enzymes (cytochrome p450) and p-glycoprotein transporter and may reduce the effectiveness of contraceptive steroids. this may also result in breakthrough bleeding. increase in plasma hormone levels associated with coadministered drugs : coadministration of atorvastatin and certain ethinyl estradiol containing oral contraceptives increased auc values for ethinyl estradiol by approximately 20%. ascorbic acid and acetaminophen may increase plasma ethinyl estradiol levels, possibly by inhibition of conjugation. cyp 3a4 inhibitors such as itraconazole or ketoconazole may increase plasma hormone levels. changes in plasma levels of coadministered drugs : combination hormonal contraceptives containing some synthetic estrogens (e.g., ethinyl estradiol) may inhibit the metabolism of other compounds. increased plasma concentrations of cyclosporine, prednisolone, and theophylline have been reported with concomitant administration of oral contraceptives. decreased plasma concentrations of acetaminophen and increased clearance of temazepam, salicylic acid, morphine, and clofibric acid have been noted when these drugs were administered with oral contraceptives. no formal drug-drug interaction studies were conducted with velivet.

hance § 85 85 spermicides ¶ 26 6 40 periodic abstinence 25 63 calendar 9 ovulation method 3 sympto-thermal # 2 post-ovulation 1 withdrawal 19 4 cap Þ parous women 40 26 42 nulliparous women 20 9 56 sponge parous women 40 20 42 nulliparous women 20 9 56 diaphragm Þ 20 6 56 condom β female (reality) 21 5 56 male 14 3 61 pill 5 71 progestin only 0.5 combined 0.1 iud progesterone t 2.0 1.5 81 copper t 380a 0.8 0.6 78 lng 20 0.1 0.1 81 depo-provera 0.3 0.3 70 norplant and norplant-2 0.05 0.05 88 female sterilization 0.5 0.5 100 male sterilization 0.15 0.10 100 emergency contraceptive pills : treatment initiated within 72 hours after unprotected intercourse reduces risk of pregnancy by at least 75%. à lactational amenorrhea method : lam is a highly effective, temporary method of contraception. è source: trussell j, stewart f, contraceptive efficacy. in hatcher ra, trussell j, stewart f, cates w, stewart gk, kowal d, guest f, contraceptive technology: seventeenth revised edition . new york, ny: irvington publishers, 1998. * among couples attempting to avoid pregnancy, the percentage who continue to use a method for one year † among typical couples who initiate use of a method (not necessarily for the first time), the percentage who experience an accidental pregnancy during the first year if they do not stop use for any other reason ‡ among couples who initiate use of a method (not necessarily for the first time) and who use it perfectly (both consistently and correctly), the percentage who experience an accidental pregnancy during the first year if they do not stop use for any other reason à the treatment schedule is one dose within 72 hours after unprotected intercourse and a second dose 12 hours after the first dose. the food and drug administration has declared the following brands of oral contraceptives to be safe and effective for emergency contraception: ovral ® (1 dose is 2 white pills), alesse ® (1 dose is 5 pink pills), nordette ® or levlen ® (1 dose is 2 light orange pills), lo/ovral ® (1 dose is 4 white pills), triphasil ® or tri-levlen ® (1 dose is 4 yellow pills) è however, to maintain effective protection against pregnancy, another method of contraception must be used as soon as menstruation resumes, the frequency or duration of breastfeeds is reduced, bottle feeds are introduced or the baby reaches six months of age § the percentage of women becoming pregnant noted in columns (2) and (3) are based on data from populations where contraception is not used and from women who cease using contraception in order to become pregnant. among such populations, about 89% became pregnant in one year. this estimate was lowered slightly (to 85%) to represent the percentage that would become pregnant within one year among women now relying on reversible methods of contraception if they abandon contraception altogether ¶ foams, creams, gels, vaginal suppositories and vaginal film # cervical mucous (ovulation) method supplemented by calendar in the preovulatory and basal body temperature in the postovulatory phases Þ with spermicidal cream or jelly β without spermicides

following information relating to these risks. the information contained in this package insert is principally based on studies carried out in patients who used oral contraceptives with formulations of higher doses of estrogens and progestogens than those in common use today. the effect of long-term use of the oral contraceptives with formulations of lower doses of both estrogens and progestogens remains to be determined. throughout this labeling, epidemiologic studies reported are of two types: retrospective or case control studies and prospective or cohort studies. case control studies provide a measure of the relative risk of a disease, namely, a ratio of the incidence of a disease among oral contraceptive users to that among non-users. the relative risk does not provide information on the actual clinical occurrence of a disease. cohort studies provide a measure of attributable risk, which is the difference in the incidence of disease between oral contraceptive users and non-users. the attributable risk does provide information about the actual occurrence of a disease in the population (adapted from refs. 2 and 3 with the authors’ permission). for further information, the reader is referred to a text on epidemiological methods. 1. thromboembolic disorders and other vascular problems a. thromboembolism an increased risk of thromboembolic and thrombotic disease associated with the use of oral contraceptives is well established. case control studies have found the relative risk of users compared to non-users to be 3 for the first episode of superficial venous thrombosis, 4 to 11 for deep vein thrombosis or pulmonary embolism, and 1.5 to 6 for women with predisposing conditions for venous thromboembolic disease. 2, 3, 19 to 24 cohort studies have shown the relative risk to be somewhat lower, about 3 for new cases and about 4.5 for new cases requiring hospitalization. 25 the risk of thromboembolic disease associated with oral contraceptives is not related to length of use and disappears after pill use is stopped. 2 several epidemiologic studies indicate that third generation oral contraceptives, including those containing desogestrel, are associated with a higher risk of venous thromboembolism than certain second generation oral contraceptives. 102 to 104 in general, these studies indicate an approximate two-fold increased risk, which corresponds to an additional 1 to 2 cases of venous thromboembolism per 10,000 women-years of use. however, data from additional studies have not shown this two-fold increase in risk. a two- to four-fold increase in relative risk of post-operative thromboembolic complications has been reported with the use of oral contraceptives. 9, 26 the relative risk of venous thrombosis in women who have predisposing conditions is twice that of women without such medical conditions. 9, 26 if feasible, oral contraceptives should be discontinued at least four weeks prior to and for two weeks after elective surgery of a type associated with an increase in risk of thromboembolism and during and following prolonged immobilization. since the immediate postpartum period is associated with an increased risk of thromboembolism, oral contraceptives should be started no earlier than four to six weeks after delivery in women who elect not to breastfeed. b. myocardial infarction an increased risk of myocardial infarction has been attributed to oral contraceptive use. this risk is primarily in smokers or women with other underlying risk factors for coronary artery disease such as hypertension, hypercholesterolemia, morbid obesity, and diabetes. the relative risk of heart attack for current oral contraceptive users has been estimated to be two to six. 4 to 10 the risk is very low in women under the age of 30. smoking in combination with oral contraceptive use has been shown to contribute substantially to the incidence of myocardial infarction in women in their mid-thirties or older with smoking accounting for the majority of excess cases. 11 mortality rates associated with circulatory disease have been shown to increase substantially in smokers over the age of 35 and non-smokers over the age of 40 (table 3) among women who use oral contraceptives. table 3: circulatory disease mortality rates per 100,000 woman-years by age, smoking status, and oral contraceptive use. age ever-users non-smokers ever-users smokers controls non-smokers controls smokers 15 to 24 0 10.5 0 0 25 to 34 4.4 14.2 2.7 4.2 35 to 44 21.5 63.4 6.4 15.2 45+ 52.4 206.7 11.4 27.9 adapted from p.m. layde and v. beral, ref. #12. oral contraceptives may compound the effects of well-known risk factors, such as hypertension, diabetes, hyperlipidemias, age, and obesity. 13 in particular, some progestogens are known to decrease hdl cholesterol and cause glucose intolerance, while estrogens may create a state of hyperinsulinism. 14 to 18 oral contraceptives have been shown to increase blood pressure among users (see section 10 in warnings ). similar effects on risk factors have been associated with an increased risk of heart disease. oral contraceptives must be used with caution in women with cardiovascular disease risk factors. c. cerebrovascular diseases oral contraceptives have been shown to increase both the relative and attributable risks of cerebrovascular events (thrombotic and hemorrhagic strokes), although, in general, the risk is greatest among older (> 35 years), hypertensive women who also smoke. hypertension was found to be a risk factor for both users and non-users, for both types of strokes, while smoking interacted to increase the risk for hemorrhagic strokes. 27 to 29 in a large study, the relative risk of thrombotic strokes has been shown to range from 3 for normotensive users to 14 for users with severe hypertension. 30 the relative risk of hemorrhagic stroke is reported to be 1.2 for non-smokers who used oral contraceptives, 2.6 for smokers who did not use oral contraceptives, 7.6 for smokers who used oral contraceptives, 1.8 for normotensive users, and 25.7 for users with severe hypertension. 30 the attributable risk is also greater in older women. 3 oral contraceptives also increase the risk for stroke in women with other underlying risk factors such as certain inherited or acquired thrombophilias, hyperlipidemias, and obesity. women with migraine (particularly migraine with aura) who take combination oral contraceptives may be at an increased risk of stroke. d. dose-related risk of vascular disease from oral contraceptives a positive association has been observed between the amount of estrogen and progestogen in oral contraceptives and the risk of vascular disease. 31 to 33 a decline in serum high-density lipoproteins (hdl) has been reported with many progestational agents. 14 to 16 a decline in serum high-density lipoproteins has been associated with an increased incidence of ischemic heart disease. because estrogens increase hdl cholesterol, the net effect of an oral contraceptive depends on a balance achieved between doses of estrogen and progestogen and the nature and absolute amount of progestogens used in the contraceptives. the amount of both hormones should be considered in the choice of an oral contraceptive. minimizing exposure to estrogen and progestogen is in keeping with good principles of therapeutics. for any particular estrogen/progestogen combination, the dosage regimen prescribed should be one which contains the least amount of estrogen and progestogen that is compatible with a low failure rate and the needs of the individual patient. new acceptors of oral contraceptive agents should be started on a product containing the lowest hormone content that provides satisfactory results in the individual. e. persistence of risk of vascular disease there are two studies which have shown persistence of risk of vascular disease for ever-users of oral contraceptives. in a study in the united states, the risk of developing myocardial infarction after discontinuing oral contraceptives persists for at least 9 years for women 40 to 49 years old who had used oral contraceptives for five or more years, but this increased risk was not demonstrated in other age groups. 8 in another study in great britain, the risk of developing cerebrovascular disease persisted for at least 6 years after discontinuation of oral contraceptives, although excess risk was very small. 34 however, both studies were performed with oral contraceptive formulations containing 50 micrograms or more of estrogens. 2. estimates of mortality from contraceptive use one study gathered data from a variety of sources which have estimated the mortality rate associated with different methods of contraception at different ages (table 4). these estimates include the combined risk of death associated with contraceptive methods plus the risk attributable to pregnancy in the event of method failure. each method of contraception has its specific benefits and risks. the study concluded that with the exception of oral contraceptive users 35 and older who smoke and 40 and older who do not smoke, mortality associated with all methods of birth control is low and below that associated with childbirth. the observation of a possible increase in risk of mortality with age for oral contraceptive users is based on data gathered in the 1970’s - but not reported until 1983. 35 however, current clinical practice involves the use of lower estrogen formulations combined with careful restriction of oral contraceptive use to women who do not have the various risk factors listed in this labeling. because of these changes in practice and, also, because of some limited new data which suggest that the risk of cardiovascular disease with the use of oral contraceptives may now be less than previously observed, 100, 101 the fertility and maternal health drugs advisory committee was asked to review the topic in 1989. the committee concluded that although cardiovascular disease risks may be increased with oral contraceptive use after age 40 in healthy non-smoking women (even with the newer low-dose formulations), there are also greater potential health risks associated with pregnancy in older women and with the alternative surgical and medical procedures which may be necessary if such women do not have access to effective and acceptable means of contraception. therefore, the committee recommended that the benefits of low-dose oral contraceptive use by healthy non-smoking women over 40 may outweigh the possible risks. of course, older women, as all women who take oral contraceptives, should take the lowest possible dose formulation that is effective and meets the individual patient needs. table 4: annual number of birth-related or method-related deaths associated with control of fertility per 100,000 non-sterile women, by fertility control method according to age. method of control and outcome 15 to 19 20 to 24 25 to 29 30 to 34 35 to 39 40 to 44 no fertility control methods * 7 7.4 9.1 14.8 25.7 28.2 oral contraceptives non-smoker † 0.3 0.5 0.9 1.9 13.8 31.6 oral contraceptives smoker † 2.2 3.4 6.6 13.5 51.1 117.2 iud † 0.8 0.8 1 1 1.4 1.4 condom * 1.1 1.6 0.7 0.2 0.3 0.4 diaphragm/spermicide * 1.9 1.2 1.2 1.3 2.2 2.8 periodic abstinence * 2.5 1.6 1.6 1.7 2.9 3.6 adapted from h.w. ory, ref. #35. * deaths are birth related † deaths are method related 3. malignant neoplasms breast cancer velivet is contraindicated in females who currently have or have had breast cancer because breast cancer may be hormonally sensitive [see contraindications ]. epidemiology studies have not found a consistent association between use of combined oral contraceptives (cocs) and breast cancer risk. studies do not show an association between ever (current or past) use of cocs and risk of breast cancer. however, some studies report a small increase in the risk of breast cancer among current or recent users (<6 months since last use) and current users with longer duration of coc use [see postmarketing experience ]. cervical cancer some studies suggest that combination oral contraceptive use has been associated with an increase in the risk of cervical intra-epithelial neoplasia in some populations of women. 45 to 48 however, there continues to be controversy about the extent to which such findings may be due to differences in sexual behavior and other factors. in spite of many studies of the relationship between oral contraceptive use and breast and cervical cancers, a cause and-effect relationship has not been established. 4. hepatic neoplasia benign hepatic adenomas are associated with oral contraceptive use, although the incidence of benign tumors is rare in the united states. indirect calculations have estimated the attributable risk to be in the range of 3.3 cases/100,000 for users, a risk that increases after four or more years of use especially with oral contraceptives of higher dose. 49 rupture of rare, benign, hepatic adenomas may cause death through intra-abdominal hemorrhage. 50, 51 studies from britain have shown an increased risk of developing hepatocellular carcinoma 52 to 54 in long-term (> 8 years) oral contraceptive users. however, these cancers are extremely rare in the u.s. and the attributable risk (the excess incidence) of liver cancers in oral contraceptive users approaches less than one per million users. 5. risk of liver enzyme elevations with concomitant hepatitis c treatment during clinical trials with the hepatitis c combination drug regimen that contains ombitasvir/paritaprevir/ritonavir, with or without dasabuvir, alt elevations greater than 5 times the upper limit of normal (uln), including some cases greater than 20 times the uln, were significantly more frequent in women using ethinyl estradiol-containing medications such as cocs. discontinue velivet (desogestrel and ethinyl estradiol tablets) prior to starting therapy with the combination drug regimen ombitasvir/paritaprevir/ritonavir, with or without dasabuvir [see contraindications ]. velivet (desogestrel and ethinyl estradiol tablets) can be restarted approximately 2 weeks following completion of treatment with the combination drug regimen. 6. ocular lesions there have been clinical case reports of retinal thrombosis associated with the use of oral contraceptives. oral contraceptives should be discontinued if there is unexplained partial or complete loss of vision; onset of proptosis or diplopia; papilledema; or retinal vascular lesions. appropriate diagnostic and therapeutic measures should be undertaken immediately. 7. oral contraceptive use before or during early pregnancy extensive epidemiologic studies have revealed no increased risk of birth defects in women who have used oral contraceptives prior to pregnancy. 55 to 57 studies also do not suggest a teratogenic effect, particularly in so far as cardiac anomalies and limb reduction defects are concerned, 55, 56, 58, 59 when oral contraceptives are taken inadvertently during early pregnancy. the administration of oral contraceptives to induce withdrawal bleeding should not be used as a test for pregnancy. oral contraceptives should not be used during pregnancy to treat threatened or habitual abortion. it is recommended that for any patient who has missed two consecutive periods, pregnancy should be ruled out. if the patient has not adhered to the prescribed schedule, the possibility of pregnancy should be considered at the first missed period. oral contraceptive use should be discontinued if pregnancy is confirmed. 8. gallbladder disease earlier studies have reported an increased lifetime relative risk of gallbladder surgery in users of oral contraceptives and estrogens. 60, 61 more recent studies, however, have shown that the relative risk of developing gallbladder disease among oral contraceptive users may be minimal. 62 to 64 the recent findings of minimal risk may be related to the use of oral contraceptive formulations containing lower hormonal doses of estrogens and progestogens. 9. carbohydrate and lipid metabolic effects oral contraceptives have been shown to cause a decrease in glucose tolerance in a significant percentage of users. 17 oral contraceptives containing greater than 75 micrograms of estrogens cause hyperinsulinism, while lower doses of estrogen cause less glucose intolerance. 65 progestogens increase insulin secretion and create insulin resistance, this effect varying with different progestational agents. 17, 66 however, in the non-diabetic woman, oral contraceptives appear to have no effect on fasting blood glucose. 67 because of these demonstrated effects, prediabetic and diabetic women should be carefully monitored while taking oral contraceptives. a small proportion of women will have persistent hypertriglyceridemia while on the pill. as discussed earlier (see warnings 1.a. and 1.d. ), changes in serum triglycerides and lipoprotein levels have been reported in oral contraceptive users. 10. elevated blood pressure women with severe hypertension should not be started on hormonal contraceptives. an increase in blood pressure has been reported in women taking oral contraceptives 68 and this increase is more likely in older oral contraceptive users 69 and with continued use. 61 data from the royal college of general practitioners 12 and subsequent randomized trials have shown that the incidence of hypertension increases with increasing quantities of progestogens. women with a history of hypertension or hypertension-related diseases, or renal disease 70 should be encouraged to use another method of contraception. if women elect to use oral contraceptives, they should be monitored closely and if significant elevation of blood pressure occurs, oral contraceptives should be discontinued. for most women, elevated blood pressure will return to normal after stopping oral contraceptives, 69 and there is no difference in the occurrence of hypertension between ever- and never-users. 68, 70, 71 11. headache the onset or exacerbation of migraine or development of headache with a new pattern which is recurrent, persistent, or severe requires discontinuation of oral contraceptives and evaluation of the cause. 12. bleeding irregularities breakthrough bleeding and spotting are sometimes encountered in patients on oral contraceptives, especially during the first three months of use. if bleeding persists or recurs, non-hormonal causes should be considered and adequate diagnostic measures taken to rule out malignancy or pregnancy, as in the case of any abnormal vaginal bleeding. if pathology has been excluded, time or a change to another formulation may solve the problem. in the event of amenorrhea, pregnancy should be ruled out. some women may encounter post-pill amenorrhea or oligomenorrhea, especially when such a condition was pre-existent. 13. ectopic pregnancy ectopic as well as intrauterine pregnancy may occur in contraceptive failures.

tive would have been started. sunday start when initiating a sunday start regimen, another method of contraception, such as condoms or spermicide, should be used for the first 7 consecutive days of taking velivet tablets. using a sunday start, tablets are taken daily without interruption as follows: the first beige tablet should be taken on the first sunday after menstruation begins (if menstruation begins on sunday, the first beige tablet is taken on that day). tablets are then taken sequentially following the arrows marked on the dispenser. one beige tablet is taken daily for 7 days, followed by 1 orange tablet daily for 7 days, 1 pink tablet daily for 7 days, and then 1 white (inactive) tablet daily for 7 days. for all subsequent cycles, the patient then begins a new 28 tablet regimen on the next day (sunday) after taking the last white (inactive) tablet. [if switching from a sunday start oral contraceptive, the first velivet tablet should be taken on the second sunday after the last tablet of a 21 day oral contraceptive regimen or should be taken on the first sunday after the last inactive tablet of a 28 day regimen.] if a patient misses 1 active tablet in weeks 1, 2, or 3, she should take the missed tablet as soon as she remembers. if the patient misses 2 consecutive active tablets in week 1 or week 2, the patient should take 2 tablets the day she remembers and 2 tablets the next day; thereafter, the patient should resume taking 1 tablet daily until she finishes the cycle pack. the patient should be instructed to use a back-up method of birth control (such as condoms or spermicide) if she has intercourse in the 7 days after she restarts her pills. if the patient misses 2 consecutive pink (active) tablets in the third week or misses 3 or more active tablets in a row at any time during the cycle, the patient should keep taking 1 active tablet daily until the next sunday. on sunday the patient should throw out the rest of that cycle pack and start a new cycle pack that same day. the patient should be instructed to use a back-up method of birth control if she has intercourse in the 7 days after restarting her pills. complete instructions to facilitate patient counseling on proper pill usage can be found in detailed patient labeling (" how to take the pill " section). day 1 start counting the first day of menstruation as "day 1", the first beige tablet should be taken on the first day of menstrual bleeding. tablets are then taken sequentially without interruption as follows: one beige tablet daily for 7 days, then 1 orange tablet daily for 7 days, followed by 1 pink tablet daily for 7 days and then 1 white (inactive) tablet daily for 7 days. for all subsequent cycles, the patient then begins a new 28 tablet regimen on the next day after taking the last white (inactive) tablet. [if switching directly from another oral contraceptive, the first beige tablet should be taken on the same day that a new pack of the previous oral contraceptive would have been started.] if a patient misses 1 active tablet in weeks 1, 2, or 3, she should take the missed tablet as soon as she remembers. if the patient misses 2 consecutive active tablets in week 1 or week 2, the patient should take 2 tablets the day she remembers and 2 tablets the next day; thereafter, the patient should resume taking 1 tablet daily until she finishes the cycle pack. the patient should be instructed to use a back-up method of birth control (such as condoms or spermicide) if she has intercourse in the 7 days after she restarts her pills. if the patient misses 2 consecutive pink tablets in the third week or misses 3 or more active tablets in a row at any time during the cycle, the patient should throw out the rest of that cycle pack and start a new cycle pack that same day. the patient should be instructed to use a back-up method of birth control if she has intercourse in the 7 days after restarting her pills. complete instructions to facilitate patient counseling on proper pill usage can be found in detailed patient labeling (" how to take the pill " section). additional instructions for both sunday and day 1 starts if spotting or breakthrough bleeding occurs breakthrough bleeding, spotting, and amenorrhea are frequent reasons for patients discontinuing oral contraceptives. in breakthrough bleeding, as in all cases of irregular bleeding from the vagina, non-functional causes should be considered. in undiagnosed persistent or recurrent abnormal bleeding from the vagina, adequate diagnostic measures are indicated to rule out pregnancy or malignancy. if both pregnancy and pathology have been excluded, time or a change to another preparation may solve the problem. changing to an oral contraceptive with a higher estrogen content, while potentially useful in minimizing menstrual irregularity, should be done only if necessary since this may increase the risk of thromboembolic disease. use of velivet in the event of a missed menstrual period 1. if the patient has not adhered to the prescribed schedule, the possibility of pregnancy should be considered at the time of the first missed period and oral contraceptive use should be discontinued if pregnancy is confirmed. 2. if the patient has adhered to the prescribed regimen and misses two consecutive periods, pregnancy should be ruled out. oral contraceptive use should be discontinued if pregnancy is confirmed. use of velivet postpartum the use of velivet for contraception may be initiated 4 to 6 weeks postpartum in women who elect not to breastfeed. when the tablets are administered during the postpartum period, the increased risk of thromboembolic disease associated with the postpartum period must be considered (see contraindications and warnings concerning thromboembolic disease. see also precautions , nursing mothers ). if the patient starts on velivet postpartum, and has not yet had a period, she should be instructed to use another method of contraception until a beige tablet has been taken daily for 7 consecutive days.

use” are females that never used cocs. an increased risk of the following serious adverse reactions has been associated with the use of oral contraceptives (see warnings section): thrombophlebitis and venous thrombosis with or without embolism arterial thromboembolism pulmonary embolism myocardial infarction cerebral hemorrhage cerebral thrombosis hypertension gallbladder disease hepatic adenomas or benign liver tumors there is evidence of an association between the following conditions and the use of oral contraceptives: mesenteric thrombosis retinal thrombosis the following adverse reactions have been reported in patients receiving oral contraceptives and are believed to be drug-related: nausea vomiting gastrointestinal symptoms (such as abdominal pain, cramps and bloating) breakthrough bleeding spotting change in menstrual flow amenorrhea temporary infertility after discontinuation of treatment edema/fluid retention melasma/chloasma which may persist breast changes: tenderness, pain, enlargement, and secretion decrease in serum folate levels exacerbation of porphyria aggravation of varicose veins change in weight or appetite (increase or decrease) change in cervical ectropion and secretion possible diminution in lactation when given immediately postpartum cholestatic jaundice migraine headache rash (allergic) mood changes, including depression vaginitis, including candidiasis change in corneal curvature (steepening) intolerance to contact lenses exacerbation of systemic lupus erythematosus exacerbation of chorea anaphylactic/anaphylactoid reactions, including urticaria, angioedema, and severe reactions with respiratory and circulatory symptoms the following adverse reactions have been reported in users of oral contraceptives and the association has been neither confirmed nor refuted: pre-menstrual syndrome cataracts cystitis-like syndrome headache nervousness dizziness hirsutism loss of scalp hair erythema multiforme dysmenorrhea pancreatitis erythema nodosum hemorrhagic eruption impaired renal function hemolytic uremic syndrome acne changes in libido colitis budd-chiari syndrome optic neuritis, which may lead to partial or complete loss of vision 1

is unknown. b. anti-hiv protease inhibitors several of the anti-hiv protease inhibitors have been studied with coadministration of oral combination hormonal contraceptives; significant changes (increase and decrease) in the plasma levels of the estrogen and progestin have been noted in some cases. the efficacy and safety of these oral contraceptive products may be affected with coadministration of anti-hiv protease inhibitors. healthcare providers should refer to the label of the individual anti-hiv protease inhibitors for further drug-drug interaction information. concomitant use with hcv combination therapy – liver enzyme elevation do not co-administer velivet (desogestrel and ethinyl estradiol tablets) with hcv drug combinations containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir, due to potential for alt elevations (see warnings, risk of liver enzyme elevations with concomitant hepatitis c treatment ). c. herbal products herbal products containing st. john’s wort (hypericum perforatum) may induce hepatic enzymes (cytochrome p450) and p-glycoprotein transporter and may reduce the effectiveness of contraceptive steroids. this may also result in breakthrough bleeding. increase in plasma hormone levels associated with coadministered drugs : coadministration of atorvastatin and certain ethinyl estradiol containing oral contraceptives increased auc values for ethinyl estradiol by approximately 20%. ascorbic acid and acetaminophen may increase plasma ethinyl estradiol levels, possibly by inhibition of conjugation. cyp 3a4 inhibitors such as itraconazole or ketoconazole may increase plasma hormone levels. changes in plasma levels of coadministered drugs : combination hormonal contraceptives containing some synthetic estrogens (e.g., ethinyl estradiol) may inhibit the metabolism of other compounds. increased plasma concentrations of cyclosporine, prednisolone, and theophylline have been reported with concomitant administration of oral contraceptives. decreased plasma concentrations of acetaminophen and increased clearance of temazepam, salicylic acid, morphine, and clofibric acid have been noted when these drugs were administered with oral contraceptives. no formal drug-drug interaction studies were conducted with velivet.

tradiol, compared to solution, as measured by serum levels of etonogestrel, is approximately 100%. ethinyl estradiol is rapidly and almost completely absorbed. when the lowest and highest tablet strengths, 0.100 mg desogestrel/0.025 mg ethinyl estradiol and 0.150 mg desogestrel/0.025 mg ethinyl estradiol, were compared to solution, the relative bioavailability of ethinyl estradiol was 92% and 98%, respectively. the effect of food on the bioavailability of desogestrel and ethinyl estradiol tablets following oral administration has not been evaluated. the pharmacokinetics of etonogestrel and ethinyl estradiol following multiple dose administration of desogestrel and ethinyl estradiol tablets were determined during the third cycle in 21 subjects. after multiple dosing with desogestrel and ethinyl estradiol tablets, plasma concentrations of etonogestrel reached steady-state after four days of treatment during dosing phases 1 and 3. during dosing phase 2, steady-state was reached after five days of treatment. the dose-normalized auc 0 - 24 for etonogestrel was increased approximately 20% from phase 1 to phase 2 and approximately 10% from phase 2 to phase 3. shbg concentrations were shown to be induced by the daily administration of ethinyl estradiol. steady state for ethinyl estradiol was reached after four days of dosing in all dosing phases. the pharmacokinetic parameters of etonogestrel and ethinyl estradiol during the third cycle following multiple dose administration of desogestrel and ethinyl estradiol tablets are summarized in table 1. table 1: mean (sd) pharmacokinetic parameters of desogestrel and ethinyl estradiol tablets over a 28-day dosing period in the third cycle (n = 21). etonogestrel phase dose* c max t max n-auc 0-24 cl/f (days) mg pg/ml hr pg•hr/ml/mcg l/hr 1 (1 to 7) 0.100 2163.3 (856.4) 1.6 (0.7) 196.0 (75.4) 6.1 (2.3) 2 (8 to 14) 0.125 3241.5 (1296.5) † 1.1 (0.3) † 234.4 (85) † 5.1 (1.9) † 3 (15 to 21) 0.150 3855.7 (1273.1) 1.5 (0.8) 256.6 (104) 4.6 (1.6) ethinyl estradiol phase dose c max t max n-auc 0-24 cl/f (days) mg pg/ml hr pg•hr/ml/mcg l/hr 1 (1 to 7) 0.025 85.4 (51.7) 1.5 (0.8) 26.4 (11.5) 43.5 (15) 2 (8 to 14) 0.025 91.3 (52.2) † 1.2 (1.2) † 29 (15.5) † 41.7 (15.5) † 3 (15 to 21) 0.025 90.1 (48.2) 1.2 (0.7) 28.3 (13.2) 42.5 (18.7) c max – maximum serum drug concentration t max – time at which maximum serum drug concentration occurs n-auc 0-24 – area under the concentration- vs. time curve -0 to 24 hours normalized to 1 mcg administered cl/f – apparent clearance note: for information on t 1/2 for day 21, see the excretion section. * desogestrel † n = 20 distribution etonogestrel, the active metabolite of desogestrel, was found to be 98% protein bound, primarily to sex hormone-binding globulin (shbg). ethinyl estradiol is primarily bound to plasma albumin. ethinyl estradiol does not bind to shbg, but induces shbg synthesis. desogestrel, in combination with ethinyl estradiol, does not counteract the estrogen-induced increase in shbg, resulting in lower serum levels of free testosterone. 96 to 99 metabolism desogestrel desogestrel is rapidly and completely metabolized by hydroxylation in the intestinal mucosa and on first pass through the liver to etonogestrel. in vitro data suggest an important role for the cytochrome p450 cyp2c9 in the bioactivation of desogestrel. further metabolism of etonogestrel into 6β-hydroxy, etonogestrel and 6β-13ethyl-dihydroxylated metabolites as major metabolites is catalyzed by cyp3a4. other metabolites (i.e., 3α-oh-desogestrel, 3β-oh-desogestrel, and 3α-oh-5α-h-desogestrel) also have been identified and these metabolites may undergo glucuronide and sulfate conjugation. ethinyl estradiol ethinyl estradiol is subject to a significant degree of presystemic conjugation (phase ii metabolism). ethinyl estradiol, escaping gut wall conjugation, undergoes phase i metabolism and hepatic conjugation (phase ii metabolism). major phase i metabolites are 2-oh-ethinyl estradiol and 2-methoxy-ethinyl estradiol. sulfate and glucuronide conjugates of both ethinyl estradiol and phase i metabolites, which are excreted in bile, can undergo enterohepatic circulation. excretion etonogestrel and ethinyl estradiol are primarily eliminated in urine, bile and feces. at steady state, on day 21, the elimination half-lives of etonogestrel and ethinyl estradiol are 37.1 ± 14.8 hours and 28.2 ± 10.5 hours, respectively. special populations race there is no information to determine the effect of race on the pharmacokinetics of desogestrel and ethinyl estradiol tablets. hepatic insufficiency no formal studies were conducted to evaluate the effect of hepatic disease on the disposition of desogestrel and ethinyl estradiol tablets. however, steroid hormones may be poorly metabolized in patients with impaired liver function (see precautions ). renal insufficiency no formal studies were conducted to evaluate the effect of renal disease on the disposition of desogestrel and ethinyl estradiol tablets. drug-drug interactions interactions between desogestrel/ethinyl estradiol and other drugs have been reported in the literature. no formal drug-drug interaction studies were conducted with desogestrel and ethinyl estradiol tablets (see precautions ).

to 25°c (68° to 77°f) [see usp controlled room temperature]. keep this and all medications out of the reach of children.